Vered Bisker-Leib - 19 Jan 2023 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Vered Bisker-Leib
Issuer symbol
N/A
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
23 Jan 2023, 17:17:33 UTC
Previous filing
25 Nov 2022
Next filing
09 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADXS Stock Option Award +1,639 1,639 19 Jan 2023 Common Stock 1,639 $58.59 Direct F1, F2
transaction ADXS Stock Option Award +1,171 1,171 19 Jan 2023 Common Stock 1,171 $55.23 Direct F3, F4
transaction ADXS Stock Option Award +1,171 1,171 19 Jan 2023 Common Stock 1,171 $8.69 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in thirty-six substantially equal monthly installments, such that the option shall be fully vested on August 18, 2023.
F2 Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 8,750 shares of the common stock of Old Ayala for $10.98 per share.
F3 This option is fully vested and exercisable.
F4 Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share.
F5 This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
F6 Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share.